Cayman
Showing 12151–12300 of 45550 results
-
BLU-554 is a potent inhibitor of recombinant fibroblast growth factor receptor 4 (FGFR4; IC50 50 < 10 nM), a marker of FGFR4 inhibition, in MDA-MB-453 breast cancer cells.
Brand:CaymanSKU:22438 -Out of stock
BLU-554 is a potent inhibitor of recombinant fibroblast growth factor receptor 4 (FGFR4; IC50 50 < 10 nM), a marker of FGFR4 inhibition, in MDA-MB-453 breast cancer cells.
Brand:CaymanSKU:22438 -Out of stock
BLU-554 is a potent inhibitor of recombinant fibroblast growth factor receptor 4 (FGFR4; IC50 50 < 10 nM), a marker of FGFR4 inhibition, in MDA-MB-453 breast cancer cells.
Brand:CaymanSKU:22438 -Out of stock
BLU-554 is a potent inhibitor of recombinant fibroblast growth factor receptor 4 (FGFR4; IC50 50 < 10 nM), a marker of FGFR4 inhibition, in MDA-MB-453 breast cancer cells.
Brand:CaymanSKU:22438 -Out of stock
Fibroblast growth factor receptor 4 (FGFR4) is the receptor for fibroblast growth factor 19 (FGF19), which is a tightly controlled hormone that regulates bile acid synthesis and hepatocyte proliferation in the normal liver. Aberrant signaling through the FGFR4/FGF19 signaling complex has been implicated in hepatocellular carcinoma (HCC).{30600} BLU-9931 is a small molecule inhibitor of FGFR4 (IC50 = 3 nM) that is selective for FGFR4 over other FGFR family members (IC50s = 591, 493, and 150 nM for FGFR1, 2, and 3, respectively) and an extensive panel of additional kinases (selectivity score for BLU-9931 at 3 µM is 0.005).{30600} It inhibits proliferation of HCC cell lines with an activated FGFR4 signaling pathway (EC50s = 0.02-0.11 µM) and demonstrates antitumor activity when administered orally at 100 mg/kg to mice bearing HCC xenografts that overexpresses FGF19 due to amplification or to mice bearing liver tumor xenografts that overexpresses FGF19 mRNA but lack FGF19 amplification.{30600}
Brand:CaymanSKU:-Available on backorder
Fibroblast growth factor receptor 4 (FGFR4) is the receptor for fibroblast growth factor 19 (FGF19), which is a tightly controlled hormone that regulates bile acid synthesis and hepatocyte proliferation in the normal liver. Aberrant signaling through the FGFR4/FGF19 signaling complex has been implicated in hepatocellular carcinoma (HCC).{30600} BLU-9931 is a small molecule inhibitor of FGFR4 (IC50 = 3 nM) that is selective for FGFR4 over other FGFR family members (IC50s = 591, 493, and 150 nM for FGFR1, 2, and 3, respectively) and an extensive panel of additional kinases (selectivity score for BLU-9931 at 3 µM is 0.005).{30600} It inhibits proliferation of HCC cell lines with an activated FGFR4 signaling pathway (EC50s = 0.02-0.11 µM) and demonstrates antitumor activity when administered orally at 100 mg/kg to mice bearing HCC xenografts that overexpresses FGF19 due to amplification or to mice bearing liver tumor xenografts that overexpresses FGF19 mRNA but lack FGF19 amplification.{30600}
Brand:CaymanSKU:-Available on backorder
Fibroblast growth factor receptor 4 (FGFR4) is the receptor for fibroblast growth factor 19 (FGF19), which is a tightly controlled hormone that regulates bile acid synthesis and hepatocyte proliferation in the normal liver. Aberrant signaling through the FGFR4/FGF19 signaling complex has been implicated in hepatocellular carcinoma (HCC).{30600} BLU-9931 is a small molecule inhibitor of FGFR4 (IC50 = 3 nM) that is selective for FGFR4 over other FGFR family members (IC50s = 591, 493, and 150 nM for FGFR1, 2, and 3, respectively) and an extensive panel of additional kinases (selectivity score for BLU-9931 at 3 µM is 0.005).{30600} It inhibits proliferation of HCC cell lines with an activated FGFR4 signaling pathway (EC50s = 0.02-0.11 µM) and demonstrates antitumor activity when administered orally at 100 mg/kg to mice bearing HCC xenografts that overexpresses FGF19 due to amplification or to mice bearing liver tumor xenografts that overexpresses FGF19 mRNA but lack FGF19 amplification.{30600}
Brand:CaymanSKU:-Available on backorder
Fibroblast growth factor receptor 4 (FGFR4) is the receptor for fibroblast growth factor 19 (FGF19), which is a tightly controlled hormone that regulates bile acid synthesis and hepatocyte proliferation in the normal liver. Aberrant signaling through the FGFR4/FGF19 signaling complex has been implicated in hepatocellular carcinoma (HCC).{30600} BLU-9931 is a small molecule inhibitor of FGFR4 (IC50 = 3 nM) that is selective for FGFR4 over other FGFR family members (IC50s = 591, 493, and 150 nM for FGFR1, 2, and 3, respectively) and an extensive panel of additional kinases (selectivity score for BLU-9931 at 3 µM is 0.005).{30600} It inhibits proliferation of HCC cell lines with an activated FGFR4 signaling pathway (EC50s = 0.02-0.11 µM) and demonstrates antitumor activity when administered orally at 100 mg/kg to mice bearing HCC xenografts that overexpresses FGF19 due to amplification or to mice bearing liver tumor xenografts that overexpresses FGF19 mRNA but lack FGF19 amplification.{30600}
Brand:CaymanSKU:-Available on backorder
BLX3887 is an inhibitor of 15-lipoxygenase type 1 (15-LO-1; IC50 = 32 nM in a cell-free enzyme assay).{35444} It is selective for 15-LO-1 over 15-LO-2, which it does not inhibit, 5-LO (IC50 = 472 nM), and 12-LO (IC50 = 3,310 nM). BLX3887 inhibits the production of 15-LO metabolites selectively in eosinophils over neutrophils when used at a concentration of 10 µM. It also inhibits endocytosis in, and the migration of, isolated human peripheral blood mononuclear cell-derived dendritic cells in vitro.
Brand:CaymanSKU:27391 - 1 mgAvailable on backorder
BLX3887 is an inhibitor of 15-lipoxygenase type 1 (15-LO-1; IC50 = 32 nM in a cell-free enzyme assay).{35444} It is selective for 15-LO-1 over 15-LO-2, which it does not inhibit, 5-LO (IC50 = 472 nM), and 12-LO (IC50 = 3,310 nM). BLX3887 inhibits the production of 15-LO metabolites selectively in eosinophils over neutrophils when used at a concentration of 10 µM. It also inhibits endocytosis in, and the migration of, isolated human peripheral blood mononuclear cell-derived dendritic cells in vitro.
Brand:CaymanSKU:27391 - 10 mgAvailable on backorder
BLX3887 is an inhibitor of 15-lipoxygenase type 1 (15-LO-1; IC50 = 32 nM in a cell-free enzyme assay).{35444} It is selective for 15-LO-1 over 15-LO-2, which it does not inhibit, 5-LO (IC50 = 472 nM), and 12-LO (IC50 = 3,310 nM). BLX3887 inhibits the production of 15-LO metabolites selectively in eosinophils over neutrophils when used at a concentration of 10 µM. It also inhibits endocytosis in, and the migration of, isolated human peripheral blood mononuclear cell-derived dendritic cells in vitro.
Brand:CaymanSKU:27391 - 5 mgAvailable on backorder
BLX3887 is an inhibitor of 15-lipoxygenase type 1 (15-LO-1; IC50 = 32 nM in a cell-free enzyme assay).{35444} It is selective for 15-LO-1 over 15-LO-2, which it does not inhibit, 5-LO (IC50 = 472 nM), and 12-LO (IC50 = 3,310 nM). BLX3887 inhibits the production of 15-LO metabolites selectively in eosinophils over neutrophils when used at a concentration of 10 µM. It also inhibits endocytosis in, and the migration of, isolated human peripheral blood mononuclear cell-derived dendritic cells in vitro.
Brand:CaymanSKU:27391 - 500 µgAvailable on backorder
BLZ-945 is a selective inhibitor of the colony stimulating factor 1 receptor (CSF1R) with an IC50 value of 1 nM.{31423} It is more than 1,000-fold selective against its closest receptor tyrosine kinase homologs.{31423} It has been shown to inhibit CSF1-dependent proliferation with an EC50 value of 67 nM in bone marrow-derived macrophages.{31423} In glioma-bearing mice, CSF1R inhibition via BLZ-945 can block tumor progression and significantly improve survival.{31423} At 200 mg/kg, BLZ-945 decreased the growth of malignant cells in a mouse mammary tumor virus-driven polyomavirus middle T antigen model of mammary carcinogenesis and in a keratin 14-expressing human papillomavirus type 16 transgenic model of cervical carcinogenesis.{31424}
Brand:CaymanSKU:19626 -Available on backorder
BLZ-945 is a selective inhibitor of the colony stimulating factor 1 receptor (CSF1R) with an IC50 value of 1 nM.{31423} It is more than 1,000-fold selective against its closest receptor tyrosine kinase homologs.{31423} It has been shown to inhibit CSF1-dependent proliferation with an EC50 value of 67 nM in bone marrow-derived macrophages.{31423} In glioma-bearing mice, CSF1R inhibition via BLZ-945 can block tumor progression and significantly improve survival.{31423} At 200 mg/kg, BLZ-945 decreased the growth of malignant cells in a mouse mammary tumor virus-driven polyomavirus middle T antigen model of mammary carcinogenesis and in a keratin 14-expressing human papillomavirus type 16 transgenic model of cervical carcinogenesis.{31424}
Brand:CaymanSKU:19626 -Available on backorder
BLZ-945 is a selective inhibitor of the colony stimulating factor 1 receptor (CSF1R) with an IC50 value of 1 nM.{31423} It is more than 1,000-fold selective against its closest receptor tyrosine kinase homologs.{31423} It has been shown to inhibit CSF1-dependent proliferation with an EC50 value of 67 nM in bone marrow-derived macrophages.{31423} In glioma-bearing mice, CSF1R inhibition via BLZ-945 can block tumor progression and significantly improve survival.{31423} At 200 mg/kg, BLZ-945 decreased the growth of malignant cells in a mouse mammary tumor virus-driven polyomavirus middle T antigen model of mammary carcinogenesis and in a keratin 14-expressing human papillomavirus type 16 transgenic model of cervical carcinogenesis.{31424}
Brand:CaymanSKU:19626 -Available on backorder
BLZ-945 is a selective inhibitor of the colony stimulating factor 1 receptor (CSF1R) with an IC50 value of 1 nM.{31423} It is more than 1,000-fold selective against its closest receptor tyrosine kinase homologs.{31423} It has been shown to inhibit CSF1-dependent proliferation with an EC50 value of 67 nM in bone marrow-derived macrophages.{31423} In glioma-bearing mice, CSF1R inhibition via BLZ-945 can block tumor progression and significantly improve survival.{31423} At 200 mg/kg, BLZ-945 decreased the growth of malignant cells in a mouse mammary tumor virus-driven polyomavirus middle T antigen model of mammary carcinogenesis and in a keratin 14-expressing human papillomavirus type 16 transgenic model of cervical carcinogenesis.{31424}
Brand:CaymanSKU:19626 -Available on backorder
Thromboxane A2 (TXA2) is a potent thrombogenic and vasoconstrictor eicosanoid, produced in large quantities by activated platelets. TXA2 has been implicated as a causal factor in the onset of stroke and myocardial infarction. BM 567 is a dual acting antithrombogenic agent, acting as an inhibitor of thromboxane A2 (TXA2) synthase and as an antagonist of the TP receptor, the G protein-coupled receptor mediating TXA2 activity in platelets and vascular smooth muscle. BM 567 antagonizes the vascular smooth muscle TP receptor with an IC50 value of 1.1 nM. It inhibits platelet TX synthase with an IC50 value of 12 nM.{12979}
Brand:CaymanSKU:10155 - 1 mgAvailable on backorder
Thromboxane A2 (TXA2) is a potent thrombogenic and vasoconstrictor eicosanoid, produced in large quantities by activated platelets. TXA2 has been implicated as a causal factor in the onset of stroke and myocardial infarction. BM 567 is a dual acting antithrombogenic agent, acting as an inhibitor of thromboxane A2 (TXA2) synthase and as an antagonist of the TP receptor, the G protein-coupled receptor mediating TXA2 activity in platelets and vascular smooth muscle. BM 567 antagonizes the vascular smooth muscle TP receptor with an IC50 value of 1.1 nM. It inhibits platelet TX synthase with an IC50 value of 12 nM.{12979}
Brand:CaymanSKU:10155 - 10 mgAvailable on backorder
Thromboxane A2 (TXA2) is a potent thrombogenic and vasoconstrictor eicosanoid, produced in large quantities by activated platelets. TXA2 has been implicated as a causal factor in the onset of stroke and myocardial infarction. BM 567 is a dual acting antithrombogenic agent, acting as an inhibitor of thromboxane A2 (TXA2) synthase and as an antagonist of the TP receptor, the G protein-coupled receptor mediating TXA2 activity in platelets and vascular smooth muscle. BM 567 antagonizes the vascular smooth muscle TP receptor with an IC50 value of 1.1 nM. It inhibits platelet TX synthase with an IC50 value of 12 nM.{12979}
Brand:CaymanSKU:10155 - 5 mgAvailable on backorder
BM212 is an antimycobacterial compound.{37196} It inhibits the growth of laboratory and clinical isolate M. tuberculosis strains (MICs = 0.7-1.5 μg/ml), including strains resistant to ethambutol (Item No. 23713), isoniazid (Item No. 20378), rifampicin (Item No. 14423), and rifabutin (Item No. 16468). BM212 also inhibits the growth of M. fortuitum, M. smegmatis, M. kansasii, and M. avium strains (MICs = 3.1-12.5, 3.1-25, 3.1-6.2, and 0.4-3.1 μg/ml, respectively). It inhibits replication of intracellular M. tuberculosis in infected U937 macrophages in a dose-dependent manner at concentrations ranging from 0.5-10 μg/ml. Some M. smegmatis, M. bovis BCG, and M. tuberculosis H37Rv mutant strains carry mutations in the mycobacterium membrane protein large 3 (mmpL3) gene and are resistant to BM212, indicating mmpL3 is likely a cellular target of BM212.{37197}
Brand:CaymanSKU:22986 - 1 mgAvailable on backorder
BM212 is an antimycobacterial compound.{37196} It inhibits the growth of laboratory and clinical isolate M. tuberculosis strains (MICs = 0.7-1.5 μg/ml), including strains resistant to ethambutol (Item No. 23713), isoniazid (Item No. 20378), rifampicin (Item No. 14423), and rifabutin (Item No. 16468). BM212 also inhibits the growth of M. fortuitum, M. smegmatis, M. kansasii, and M. avium strains (MICs = 3.1-12.5, 3.1-25, 3.1-6.2, and 0.4-3.1 μg/ml, respectively). It inhibits replication of intracellular M. tuberculosis in infected U937 macrophages in a dose-dependent manner at concentrations ranging from 0.5-10 μg/ml. Some M. smegmatis, M. bovis BCG, and M. tuberculosis H37Rv mutant strains carry mutations in the mycobacterium membrane protein large 3 (mmpL3) gene and are resistant to BM212, indicating mmpL3 is likely a cellular target of BM212.{37197}
Brand:CaymanSKU:22986 - 10 mgAvailable on backorder
BM212 is an antimycobacterial compound.{37196} It inhibits the growth of laboratory and clinical isolate M. tuberculosis strains (MICs = 0.7-1.5 μg/ml), including strains resistant to ethambutol (Item No. 23713), isoniazid (Item No. 20378), rifampicin (Item No. 14423), and rifabutin (Item No. 16468). BM212 also inhibits the growth of M. fortuitum, M. smegmatis, M. kansasii, and M. avium strains (MICs = 3.1-12.5, 3.1-25, 3.1-6.2, and 0.4-3.1 μg/ml, respectively). It inhibits replication of intracellular M. tuberculosis in infected U937 macrophages in a dose-dependent manner at concentrations ranging from 0.5-10 μg/ml. Some M. smegmatis, M. bovis BCG, and M. tuberculosis H37Rv mutant strains carry mutations in the mycobacterium membrane protein large 3 (mmpL3) gene and are resistant to BM212, indicating mmpL3 is likely a cellular target of BM212.{37197}
Brand:CaymanSKU:22986 - 5 mgAvailable on backorder
BMDB (hydrochloride) (Item No. 24062) is an analytical reference standard categorized as a cathinone.{50425} This product is intended for research and forensic applications.
Brand:CaymanSKU:24062 - 1 mgAvailable on backorder
BMDB (hydrochloride) (Item No. 24062) is an analytical reference standard categorized as a cathinone.{50425} This product is intended for research and forensic applications.
Brand:CaymanSKU:24062 - 5 mgAvailable on backorder
BMH-21 is an inhibitor of RNA polymerase I.{41313} It binds to GC-rich sequences in DNA and ribosomal DNA (rDNA) and inhibits RNA polymerase I transcription in vitro. It inhibits expression of the 47S rRNA transcript (IC50 = 60 nM), disrupts the structure of the nucleolus, and leads to removal of the RNA polymerase complex from rDNA by inducing dissociation and destruction of RPA194 through a proteasome-dependent mechanism. BMH-21 also activates p53 in the nanomolar range.{41312} It reduces viability of several cancer cell lines but not of non-cancerous cells (IC50s = 0.7, 1.9, ≥40, and 2.7 µM for A375, human diploid fibroblasts, primary human melanocytes, and HIMEC cells, respectively). BMH-21 intercalates with DNA but does not induce DNA damage via the ataxia-telangiectasia mutated (ATM) kinase pathway. BMH-21 (25 mg/kg) inhibits tumor growth in melanoma and colon cancer mouse xenograft models.{41313}
Brand:CaymanSKU:22282 -Out of stock
BMH-21 is an inhibitor of RNA polymerase I.{41313} It binds to GC-rich sequences in DNA and ribosomal DNA (rDNA) and inhibits RNA polymerase I transcription in vitro. It inhibits expression of the 47S rRNA transcript (IC50 = 60 nM), disrupts the structure of the nucleolus, and leads to removal of the RNA polymerase complex from rDNA by inducing dissociation and destruction of RPA194 through a proteasome-dependent mechanism. BMH-21 also activates p53 in the nanomolar range.{41312} It reduces viability of several cancer cell lines but not of non-cancerous cells (IC50s = 0.7, 1.9, ≥40, and 2.7 µM for A375, human diploid fibroblasts, primary human melanocytes, and HIMEC cells, respectively). BMH-21 intercalates with DNA but does not induce DNA damage via the ataxia-telangiectasia mutated (ATM) kinase pathway. BMH-21 (25 mg/kg) inhibits tumor growth in melanoma and colon cancer mouse xenograft models.{41313}
Brand:CaymanSKU:22282 -Out of stock
BMH-21 is an inhibitor of RNA polymerase I.{41313} It binds to GC-rich sequences in DNA and ribosomal DNA (rDNA) and inhibits RNA polymerase I transcription in vitro. It inhibits expression of the 47S rRNA transcript (IC50 = 60 nM), disrupts the structure of the nucleolus, and leads to removal of the RNA polymerase complex from rDNA by inducing dissociation and destruction of RPA194 through a proteasome-dependent mechanism. BMH-21 also activates p53 in the nanomolar range.{41312} It reduces viability of several cancer cell lines but not of non-cancerous cells (IC50s = 0.7, 1.9, ≥40, and 2.7 µM for A375, human diploid fibroblasts, primary human melanocytes, and HIMEC cells, respectively). BMH-21 intercalates with DNA but does not induce DNA damage via the ataxia-telangiectasia mutated (ATM) kinase pathway. BMH-21 (25 mg/kg) inhibits tumor growth in melanoma and colon cancer mouse xenograft models.{41313}
Brand:CaymanSKU:22282 -Out of stock
BMK ethyl glycidate (Item No. 9002713) is an analytical reference standard that is categorized as a precursor to phenylacetone (Item Nos. 16103 and 16444). Phenylacetone has been used as a precursor in the illicit synthesis of methamphetamine and amphetamine and is classified as a schedule II controlled substance in the United States.{30927,26603,26602} This product is intended for forensic and research applications.
Brand:CaymanSKU:9002713 - 10 mgAvailable on backorder
BMK ethyl glycidate (Item No. 9002713) is an analytical reference standard that is categorized as a precursor to phenylacetone (Item Nos. 16103 and 16444). Phenylacetone has been used as a precursor in the illicit synthesis of methamphetamine and amphetamine and is classified as a schedule II controlled substance in the United States.{30927,26603,26602} This product is intended for forensic and research applications.
Brand:CaymanSKU:9002713 - 5 mgAvailable on backorder
BMK ethyl glycidate (Item No. 9002713) is an analytical reference standard that is categorized as a precursor to phenylacetone (Item Nos. 16103 and 16444). Phenylacetone has been used as a precursor in the illicit synthesis of methamphetamine and amphetamine and is classified as a schedule II controlled substance in the United States.{30927,26603,26602} This product is intended for forensic and research applications.
Brand:CaymanSKU:9002713 - 50 mgAvailable on backorder
BMK glycidic acid (Item No. 19682) is an analytical reference standard that is categorized as a precursor to the production of phenylacetone (Item Nos. 16103 | 16444). Phenylacetone has been used as a precursor in the illicit synthesis of methamphetamine and amphetamine and is classified as a schedule II controlled substance in the United States.{30927,26603,26602} This product is intended for forensic and research applications.
Brand:CaymanSKU:19682 -Available on backorder
BMK glycidic acid (Item No. 19682) is an analytical reference standard that is categorized as a precursor to the production of phenylacetone (Item Nos. 16103 | 16444). Phenylacetone has been used as a precursor in the illicit synthesis of methamphetamine and amphetamine and is classified as a schedule II controlled substance in the United States.{30927,26603,26602} This product is intended for forensic and research applications.
Brand:CaymanSKU:19682 -Available on backorder
BMK methyl glycidate (Item No. 9002714) is an analytical reference standard that is categorized as a precursor to phenylacetone (Item Nos. 16103 and 16444). Phenylacetone has been used as a precursor in the illicit synthesis of methamphetamine and amphetamine and is classified as a schedule II controlled substance in the United States.{30927,26603,26602} This product is intended for forensic and research applications.
Brand:CaymanSKU:9002714 - 10 mgAvailable on backorder
BMK methyl glycidate (Item No. 9002714) is an analytical reference standard that is categorized as a precursor to phenylacetone (Item Nos. 16103 and 16444). Phenylacetone has been used as a precursor in the illicit synthesis of methamphetamine and amphetamine and is classified as a schedule II controlled substance in the United States.{30927,26603,26602} This product is intended for forensic and research applications.
Brand:CaymanSKU:9002714 - 5 mgAvailable on backorder
BMK methyl glycidate (Item No. 9002714) is an analytical reference standard that is categorized as a precursor to phenylacetone (Item Nos. 16103 and 16444). Phenylacetone has been used as a precursor in the illicit synthesis of methamphetamine and amphetamine and is classified as a schedule II controlled substance in the United States.{30927,26603,26602} This product is intended for forensic and research applications.
Brand:CaymanSKU:9002714 - 50 mgAvailable on backorder
Inhibition of histone deacetylase (HDAC) enzymes by compounds such as trichostatin A can have wide ranging effects in cancer, cell differentiation, and other aspects of gene expression regulation.{10663} BML-210 is a small molecule inhibitor of HDAC with an IC50 value of 30 µM when tested in HeLa cell nuclear extracts using 200 µM acetylated fluorometric substrate{14835} (substrate available in Cayman’s HDAC Activity and Inhibitor Screening Assay Kits – Item Nos. 10011563 and 10011564).
Brand:CaymanSKU:10005019 - 1 mgAvailable on backorder
Inhibition of histone deacetylase (HDAC) enzymes by compounds such as trichostatin A can have wide ranging effects in cancer, cell differentiation, and other aspects of gene expression regulation.{10663} BML-210 is a small molecule inhibitor of HDAC with an IC50 value of 30 µM when tested in HeLa cell nuclear extracts using 200 µM acetylated fluorometric substrate{14835} (substrate available in Cayman’s HDAC Activity and Inhibitor Screening Assay Kits – Item Nos. 10011563 and 10011564).
Brand:CaymanSKU:10005019 - 10 mgAvailable on backorder
Inhibition of histone deacetylase (HDAC) enzymes by compounds such as trichostatin A can have wide ranging effects in cancer, cell differentiation, and other aspects of gene expression regulation.{10663} BML-210 is a small molecule inhibitor of HDAC with an IC50 value of 30 µM when tested in HeLa cell nuclear extracts using 200 µM acetylated fluorometric substrate{14835} (substrate available in Cayman’s HDAC Activity and Inhibitor Screening Assay Kits – Item Nos. 10011563 and 10011564).
Brand:CaymanSKU:10005019 - 25 mgAvailable on backorder
Inhibition of histone deacetylase (HDAC) enzymes by compounds such as trichostatin A can have wide ranging effects in cancer, cell differentiation, and other aspects of gene expression regulation.{10663} BML-210 is a small molecule inhibitor of HDAC with an IC50 value of 30 µM when tested in HeLa cell nuclear extracts using 200 µM acetylated fluorometric substrate{14835} (substrate available in Cayman’s HDAC Activity and Inhibitor Screening Assay Kits – Item Nos. 10011563 and 10011564).
Brand:CaymanSKU:10005019 - 5 mgAvailable on backorder
BML-278 is an activator of sirtuin 1 (SIRT1) that has an EC150 value (effective concentration able to increase the enzyme by 150%) of 1 µM.{34113} It less potently activates SIRT2 and SIRT3 (EC150s = 25 and 50 µM, respectively).{34113} BML-278 induces hypoacetylation on α-tubulin in U937 cells that are pretreated with SAHA (Item No. 10009929), a histone deacetylase inhibitor. It arrests cell cycling at the G1/S phase, reduces senescence in primary human mesenchymal cells, and significantly increases mitochondrial density in murine C2C12 myoblasts.{34113}
Brand:CaymanSKU:20209 -Available on backorder
BML-278 is an activator of sirtuin 1 (SIRT1) that has an EC150 value (effective concentration able to increase the enzyme by 150%) of 1 µM.{34113} It less potently activates SIRT2 and SIRT3 (EC150s = 25 and 50 µM, respectively).{34113} BML-278 induces hypoacetylation on α-tubulin in U937 cells that are pretreated with SAHA (Item No. 10009929), a histone deacetylase inhibitor. It arrests cell cycling at the G1/S phase, reduces senescence in primary human mesenchymal cells, and significantly increases mitochondrial density in murine C2C12 myoblasts.{34113}
Brand:CaymanSKU:20209 -Available on backorder
BML-278 is an activator of sirtuin 1 (SIRT1) that has an EC150 value (effective concentration able to increase the enzyme by 150%) of 1 µM.{34113} It less potently activates SIRT2 and SIRT3 (EC150s = 25 and 50 µM, respectively).{34113} BML-278 induces hypoacetylation on α-tubulin in U937 cells that are pretreated with SAHA (Item No. 10009929), a histone deacetylase inhibitor. It arrests cell cycling at the G1/S phase, reduces senescence in primary human mesenchymal cells, and significantly increases mitochondrial density in murine C2C12 myoblasts.{34113}
Brand:CaymanSKU:20209 -Available on backorder
BML-278 is an activator of sirtuin 1 (SIRT1) that has an EC150 value (effective concentration able to increase the enzyme by 150%) of 1 µM.{34113} It less potently activates SIRT2 and SIRT3 (EC150s = 25 and 50 µM, respectively).{34113} BML-278 induces hypoacetylation on α-tubulin in U937 cells that are pretreated with SAHA (Item No. 10009929), a histone deacetylase inhibitor. It arrests cell cycling at the G1/S phase, reduces senescence in primary human mesenchymal cells, and significantly increases mitochondrial density in murine C2C12 myoblasts.{34113}
Brand:CaymanSKU:20209 -Available on backorder
BMN 673 is an orally available poly(ADP-ribose) polymerase (PARP) inhibitor with an IC50 value of 0.57 nM.{32032} It similarly binds to PARP1 and PARP2 with Ki values of 1.2 and 0.85 nM, respectively, but has no effect on PARG.{32032} BMN 673 selectively targets tumor cells with BRCA1, BRCA2, or PTEN gene mutations and elicits antitumor activity in xenografted tumors in mice.{32032}
Brand:CaymanSKU:19782 -Available on backorder
BMN 673 is an orally available poly(ADP-ribose) polymerase (PARP) inhibitor with an IC50 value of 0.57 nM.{32032} It similarly binds to PARP1 and PARP2 with Ki values of 1.2 and 0.85 nM, respectively, but has no effect on PARG.{32032} BMN 673 selectively targets tumor cells with BRCA1, BRCA2, or PTEN gene mutations and elicits antitumor activity in xenografted tumors in mice.{32032}
Brand:CaymanSKU:19782 -Available on backorder
BMN 673 is an orally available poly(ADP-ribose) polymerase (PARP) inhibitor with an IC50 value of 0.57 nM.{32032} It similarly binds to PARP1 and PARP2 with Ki values of 1.2 and 0.85 nM, respectively, but has no effect on PARG.{32032} BMN 673 selectively targets tumor cells with BRCA1, BRCA2, or PTEN gene mutations and elicits antitumor activity in xenografted tumors in mice.{32032}
Brand:CaymanSKU:19782 -Available on backorder
BMN 673 is an orally available poly(ADP-ribose) polymerase (PARP) inhibitor with an IC50 value of 0.57 nM.{32032} It similarly binds to PARP1 and PARP2 with Ki values of 1.2 and 0.85 nM, respectively, but has no effect on PARG.{32032} BMN 673 selectively targets tumor cells with BRCA1, BRCA2, or PTEN gene mutations and elicits antitumor activity in xenografted tumors in mice.{32032}
Brand:CaymanSKU:19782 -Available on backorder
BMP-22 is an inhibitor of autotaxin (IC50 = 170 nM).{35710} It is selective for autotaxin over the phosphodiesterases NPP6 and NPP7 at 10 μM. BMP-22 (0.1-1,000 nM) inhibits autotaxin-mediated production of lysophosphatidic acid (LPA) from lysophosphatidylcholine (LPC; Item No. 24331) in vitro in a concentration-dependent manner. It inhibits LPC-dependent MM1 cell invasion of a human umbilical vein endothelial cell (HUVEC) monolayer. BMP-22 (0.5 mg/kg per day) decreases the number of lung metastatic foci in a B16/F10 syngeneic mouse melanoma model of lung metastasis.
Brand:CaymanSKU:27264 - 1 mgAvailable on backorder
BMP-22 is an inhibitor of autotaxin (IC50 = 170 nM).{35710} It is selective for autotaxin over the phosphodiesterases NPP6 and NPP7 at 10 μM. BMP-22 (0.1-1,000 nM) inhibits autotaxin-mediated production of lysophosphatidic acid (LPA) from lysophosphatidylcholine (LPC; Item No. 24331) in vitro in a concentration-dependent manner. It inhibits LPC-dependent MM1 cell invasion of a human umbilical vein endothelial cell (HUVEC) monolayer. BMP-22 (0.5 mg/kg per day) decreases the number of lung metastatic foci in a B16/F10 syngeneic mouse melanoma model of lung metastasis.
Brand:CaymanSKU:27264 - 10 mgAvailable on backorder
BMP-22 is an inhibitor of autotaxin (IC50 = 170 nM).{35710} It is selective for autotaxin over the phosphodiesterases NPP6 and NPP7 at 10 μM. BMP-22 (0.1-1,000 nM) inhibits autotaxin-mediated production of lysophosphatidic acid (LPA) from lysophosphatidylcholine (LPC; Item No. 24331) in vitro in a concentration-dependent manner. It inhibits LPC-dependent MM1 cell invasion of a human umbilical vein endothelial cell (HUVEC) monolayer. BMP-22 (0.5 mg/kg per day) decreases the number of lung metastatic foci in a B16/F10 syngeneic mouse melanoma model of lung metastasis.
Brand:CaymanSKU:27264 - 25 mgAvailable on backorder
BMP-22 is an inhibitor of autotaxin (IC50 = 170 nM).{35710} It is selective for autotaxin over the phosphodiesterases NPP6 and NPP7 at 10 μM. BMP-22 (0.1-1,000 nM) inhibits autotaxin-mediated production of lysophosphatidic acid (LPA) from lysophosphatidylcholine (LPC; Item No. 24331) in vitro in a concentration-dependent manner. It inhibits LPC-dependent MM1 cell invasion of a human umbilical vein endothelial cell (HUVEC) monolayer. BMP-22 (0.5 mg/kg per day) decreases the number of lung metastatic foci in a B16/F10 syngeneic mouse melanoma model of lung metastasis.
Brand:CaymanSKU:27264 - 5 mgAvailable on backorder
BMPO is a cyclic nitrone spin trap that can be used for the detection and characterization of thiyl radicals, hydroxyl radicals, and superoxide anions in vitro or in vivo.{24291} The BMPO-superoxide adduct does not rapidly decompose to the hydroxyl adduct in cells (t½ = 23 min).{24291,17433} Also, the ESR spectrum of the BMPO-glutathionyl adduct does not fully overlap with the spectrum of its hydroxyl adduct.{24291} Purified by crystallization and stored as a solid, BMPO has a longer shelf life than liquid spin traps.{17433}
Brand:CaymanSKU:- BMPO is a cyclic nitrone spin trap that can be used for the detection and characterization of thiyl radicals, hydroxyl radicals, and superoxide anions in vitro or in vivo.{24291} The BMPO-superoxide adduct does not rapidly decompose to the hydroxyl adduct in cells (t½ = 23 min).{24291,17433} Also, the ESR spectrum of the BMPO-glutathionyl adduct does not fully overlap with the spectrum of its hydroxyl adduct.{24291} Purified by crystallization and stored as a solid, BMPO has a longer shelf life than liquid spin traps.{17433}
Brand:CaymanSKU:- BMPO is a cyclic nitrone spin trap that can be used for the detection and characterization of thiyl radicals, hydroxyl radicals, and superoxide anions in vitro or in vivo.{24291} The BMPO-superoxide adduct does not rapidly decompose to the hydroxyl adduct in cells (t½ = 23 min).{24291,17433} Also, the ESR spectrum of the BMPO-glutathionyl adduct does not fully overlap with the spectrum of its hydroxyl adduct.{24291} Purified by crystallization and stored as a solid, BMPO has a longer shelf life than liquid spin traps.{17433}
Brand:CaymanSKU:- BMPO is a cyclic nitrone spin trap that can be used for the detection and characterization of thiyl radicals, hydroxyl radicals, and superoxide anions in vitro or in vivo.{24291} The BMPO-superoxide adduct does not rapidly decompose to the hydroxyl adduct in cells (t½ = 23 min).{24291,17433} Also, the ESR spectrum of the BMPO-glutathionyl adduct does not fully overlap with the spectrum of its hydroxyl adduct.{24291} Purified by crystallization and stored as a solid, BMPO has a longer shelf life than liquid spin traps.{17433}
Brand:CaymanSKU:-
BMS 1166 is an inhibitor of the interaction between programmed cell death 1 (PD-1) and its ligand PD-L1 that has an IC50 value of 1.4 nM in a homologous time-resolved fluorescence (HTRF) assay.{40457} It increases the activation of Jurkat cells expressing PD-1 in co-culture with CHO cells expressing PD-L1 (EC50 = 276 nM in a reporter assay).{59193}
Brand:CaymanSKU:31441 - 1 mgAvailable on backorder
BMS 1166 is an inhibitor of the interaction between programmed cell death 1 (PD-1) and its ligand PD-L1 that has an IC50 value of 1.4 nM in a homologous time-resolved fluorescence (HTRF) assay.{40457} It increases the activation of Jurkat cells expressing PD-1 in co-culture with CHO cells expressing PD-L1 (EC50 = 276 nM in a reporter assay).{59193}
Brand:CaymanSKU:31441 - 10 mgAvailable on backorder
BMS 1166 is an inhibitor of the interaction between programmed cell death 1 (PD-1) and its ligand PD-L1 that has an IC50 value of 1.4 nM in a homologous time-resolved fluorescence (HTRF) assay.{40457} It increases the activation of Jurkat cells expressing PD-1 in co-culture with CHO cells expressing PD-L1 (EC50 = 276 nM in a reporter assay).{59193}
Brand:CaymanSKU:31441 - 5 mgAvailable on backorder
BMS 189961 is an agonist of retinoic acid receptor ɣ (RARɣ; EC50 = 30 nM in a transactivation assay).{52154} It is selective for RARɣ over RARβ (EC50 = 1,000 nM). In vitro, BMS 189961 decreases long bone growth and digit formation of isolated mouse embryonic limb buds when used at concentrations of 0.01 and 0.1 µM.{52155} Topical administration of BMS 189661 (40 nmol) increases the skin expression of retinoid metabolism-related genes, including Rdh10, Crabp2, and Krt4, as well as epidermal barrier genes, including Spink5, Klk5, and Klk7, in mice.{52156}
Brand:CaymanSKU:29380 - 1 mgAvailable on backorder
BMS 189961 is an agonist of retinoic acid receptor ɣ (RARɣ; EC50 = 30 nM in a transactivation assay).{52154} It is selective for RARɣ over RARβ (EC50 = 1,000 nM). In vitro, BMS 189961 decreases long bone growth and digit formation of isolated mouse embryonic limb buds when used at concentrations of 0.01 and 0.1 µM.{52155} Topical administration of BMS 189661 (40 nmol) increases the skin expression of retinoid metabolism-related genes, including Rdh10, Crabp2, and Krt4, as well as epidermal barrier genes, including Spink5, Klk5, and Klk7, in mice.{52156}
Brand:CaymanSKU:29380 - 10 mgAvailable on backorder
BMS 189961 is an agonist of retinoic acid receptor ɣ (RARɣ; EC50 = 30 nM in a transactivation assay).{52154} It is selective for RARɣ over RARβ (EC50 = 1,000 nM). In vitro, BMS 189961 decreases long bone growth and digit formation of isolated mouse embryonic limb buds when used at concentrations of 0.01 and 0.1 µM.{52155} Topical administration of BMS 189661 (40 nmol) increases the skin expression of retinoid metabolism-related genes, including Rdh10, Crabp2, and Krt4, as well as epidermal barrier genes, including Spink5, Klk5, and Klk7, in mice.{52156}
Brand:CaymanSKU:29380 - 5 mgAvailable on backorder
BMS 191011 is an activator of large-conductance calcium-activated potassium (BKCa) channels that increases maximum potassium current to 126% of control in X. laevis oocytes expressing human BKCa channels when used at a concentration of 1 μM.{47157} In vivo, BMS 191011 (10-100 μg/kg, i.v.) increases the diameter of retinal arterioles without affecting blood pressure or heart rate in rats, an effect that is reversed by the BKCa channel blocker iberiotoxin (Item No. 14608).{47158}
Brand:CaymanSKU:22299 -Out of stock
BMS 191011 is an activator of large-conductance calcium-activated potassium (BKCa) channels that increases maximum potassium current to 126% of control in X. laevis oocytes expressing human BKCa channels when used at a concentration of 1 μM.{47157} In vivo, BMS 191011 (10-100 μg/kg, i.v.) increases the diameter of retinal arterioles without affecting blood pressure or heart rate in rats, an effect that is reversed by the BKCa channel blocker iberiotoxin (Item No. 14608).{47158}
Brand:CaymanSKU:22299 -Out of stock
BMS 191011 is an activator of large-conductance calcium-activated potassium (BKCa) channels that increases maximum potassium current to 126% of control in X. laevis oocytes expressing human BKCa channels when used at a concentration of 1 μM.{47157} In vivo, BMS 191011 (10-100 μg/kg, i.v.) increases the diameter of retinal arterioles without affecting blood pressure or heart rate in rats, an effect that is reversed by the BKCa channel blocker iberiotoxin (Item No. 14608).{47158}
Brand:CaymanSKU:22299 -Out of stock
BMS 191011 is an activator of large-conductance calcium-activated potassium (BKCa) channels that increases maximum potassium current to 126% of control in X. laevis oocytes expressing human BKCa channels when used at a concentration of 1 μM.{47157} In vivo, BMS 191011 (10-100 μg/kg, i.v.) increases the diameter of retinal arterioles without affecting blood pressure or heart rate in rats, an effect that is reversed by the BKCa channel blocker iberiotoxin (Item No. 14608).{47158}
Brand:CaymanSKU:22299 -Out of stock
BMS 195614 is a neutral retinoic acid receptor (RAR) α-selective antagonist (Ki = 2.5 nM).{28460} It antagonizes agonist-induced coactivator recruitment and moderately decreases SMRT binding to RAR but does not significantly affect nuclear receptor corepressor binding.{28461}
Brand:CaymanSKU:- BMS 195614 is a neutral retinoic acid receptor (RAR) α-selective antagonist (Ki = 2.5 nM).{28460} It antagonizes agonist-induced coactivator recruitment and moderately decreases SMRT binding to RAR but does not significantly affect nuclear receptor corepressor binding.{28461}
Brand:CaymanSKU:- BMS 195614 is a neutral retinoic acid receptor (RAR) α-selective antagonist (Ki = 2.5 nM).{28460} It antagonizes agonist-induced coactivator recruitment and moderately decreases SMRT binding to RAR but does not significantly affect nuclear receptor corepressor binding.{28461}
Brand:CaymanSKU:- BMS 195614 is a neutral retinoic acid receptor (RAR) α-selective antagonist (Ki = 2.5 nM).{28460} It antagonizes agonist-induced coactivator recruitment and moderately decreases SMRT binding to RAR but does not significantly affect nuclear receptor corepressor binding.{28461}
Brand:CaymanSKU:-
BMS 204352 is an activator of large-conductance calcium-activated potassium (BKCa) channels that increases BKCa currents in X. laevis oocytes expressing human BKCa in a calcium- and concentration-dependent manner.{48708} It decreases electrically induced population excitatory postsynaptic potentials (pEPSPs) in vitro in CA1 rat neurons and in anesthetized rats when administered at doses ranging from 0.005 to 1 mg/kg. BMS 204352 (0.001 and 0.3 mg/kg) reduces infarct volume in a rat model of ischemic stroke induced by middle cerebral artery occlusion (MCAO). It decreases edema in the ipsilateral hippocampus, thalamus, and adjacent cortex and time to find the platform in the Morris water maze in a rat model of fluid percussion-induced traumatic brain injury (TBI).{48709} BMS 204352 also reverses cortical hyperexcitability and reduces hyperactivity and grooming behaviors in the FmrI-/- mouse model of Fragile X syndrome.{48710} Formulations containing BMS 204352 have been used in the treatment of ischemic stroke.
Brand:CaymanSKU:29378 - 1 mgAvailable on backorder
BMS 204352 is an activator of large-conductance calcium-activated potassium (BKCa) channels that increases BKCa currents in X. laevis oocytes expressing human BKCa in a calcium- and concentration-dependent manner.{48708} It decreases electrically induced population excitatory postsynaptic potentials (pEPSPs) in vitro in CA1 rat neurons and in anesthetized rats when administered at doses ranging from 0.005 to 1 mg/kg. BMS 204352 (0.001 and 0.3 mg/kg) reduces infarct volume in a rat model of ischemic stroke induced by middle cerebral artery occlusion (MCAO). It decreases edema in the ipsilateral hippocampus, thalamus, and adjacent cortex and time to find the platform in the Morris water maze in a rat model of fluid percussion-induced traumatic brain injury (TBI).{48709} BMS 204352 also reverses cortical hyperexcitability and reduces hyperactivity and grooming behaviors in the FmrI-/- mouse model of Fragile X syndrome.{48710} Formulations containing BMS 204352 have been used in the treatment of ischemic stroke.
Brand:CaymanSKU:29378 - 10 mgAvailable on backorder
BMS 204352 is an activator of large-conductance calcium-activated potassium (BKCa) channels that increases BKCa currents in X. laevis oocytes expressing human BKCa in a calcium- and concentration-dependent manner.{48708} It decreases electrically induced population excitatory postsynaptic potentials (pEPSPs) in vitro in CA1 rat neurons and in anesthetized rats when administered at doses ranging from 0.005 to 1 mg/kg. BMS 204352 (0.001 and 0.3 mg/kg) reduces infarct volume in a rat model of ischemic stroke induced by middle cerebral artery occlusion (MCAO). It decreases edema in the ipsilateral hippocampus, thalamus, and adjacent cortex and time to find the platform in the Morris water maze in a rat model of fluid percussion-induced traumatic brain injury (TBI).{48709} BMS 204352 also reverses cortical hyperexcitability and reduces hyperactivity and grooming behaviors in the FmrI-/- mouse model of Fragile X syndrome.{48710} Formulations containing BMS 204352 have been used in the treatment of ischemic stroke.
Brand:CaymanSKU:29378 - 5 mgAvailable on backorder
BMS 214662 is a potent inhibitor of farnesyltransferase (FTase; IC50 = 1.3 nM).{53114} It is selective for FTase over geranylgeranyl transferase (GGTase; IC50 = 1,900 nM). It inhibits the growth of MEK2, A2780, and PC3 cancer cells expressing wild-type Ras (IC50s = 2.5, 0.04, and 0.15 μM, respectively), as well as HCT116, MIP, RC-165, and MIA PaCa-2 cells expressing mutant K-Ras (IC50s = 0.06, 0.3, 0.3, and 0.12 μM, respectively). BMS 214662 induces apoptosis in HCT116 cells in a concentration-dependent manner. In vivo, BMS 214662 (600 mg/kg) is curative in an HCT116 mouse xenograft model. It also reduces tumor growth in Calu-1, HT-29, EJ-1, and MIA PaCa-2 mouse xenograft models.
Brand:CaymanSKU:28713 - 1 mgAvailable on backorder
ATP citrate lyase (ACL) catalyzes the synthesis of acetyl-CoA and oxaloacetate using citrate, CoA, and ATP as substrates and Mg2+ as a cofactor.{27878} The ACL-dependent synthesis of acetyl-CoA is important for the de novo synthesis of fatty acids and cholesterol.{27877} Furthermore, as a key enzyme for linking glucose and lipid metabolism, ACL is thought to contribute to the Warburg effect in cancer cells.{27879} BMS 303141 is a cell-permeable, 2-hydroxy-N-arylbenzenesulfonamide that inhibits ACL with an IC50 value of 0.13 µM.{27876} At an oral dose of 100 mg/kg/day, BMS 303141 has been reported to reduce weight gain and lower plasma cholesterol, triglycerides, and glucose in a mouse model of hyperlipidemia.{27876}
Brand:CaymanSKU:- ATP citrate lyase (ACL) catalyzes the synthesis of acetyl-CoA and oxaloacetate using citrate, CoA, and ATP as substrates and Mg2+ as a cofactor.{27878} The ACL-dependent synthesis of acetyl-CoA is important for the de novo synthesis of fatty acids and cholesterol.{27877} Furthermore, as a key enzyme for linking glucose and lipid metabolism, ACL is thought to contribute to the Warburg effect in cancer cells.{27879} BMS 303141 is a cell-permeable, 2-hydroxy-N-arylbenzenesulfonamide that inhibits ACL with an IC50 value of 0.13 µM.{27876} At an oral dose of 100 mg/kg/day, BMS 303141 has been reported to reduce weight gain and lower plasma cholesterol, triglycerides, and glucose in a mouse model of hyperlipidemia.{27876}
Brand:CaymanSKU:- ATP citrate lyase (ACL) catalyzes the synthesis of acetyl-CoA and oxaloacetate using citrate, CoA, and ATP as substrates and Mg2+ as a cofactor.{27878} The ACL-dependent synthesis of acetyl-CoA is important for the de novo synthesis of fatty acids and cholesterol.{27877} Furthermore, as a key enzyme for linking glucose and lipid metabolism, ACL is thought to contribute to the Warburg effect in cancer cells.{27879} BMS 303141 is a cell-permeable, 2-hydroxy-N-arylbenzenesulfonamide that inhibits ACL with an IC50 value of 0.13 µM.{27876} At an oral dose of 100 mg/kg/day, BMS 303141 has been reported to reduce weight gain and lower plasma cholesterol, triglycerides, and glucose in a mouse model of hyperlipidemia.{27876}
Brand:CaymanSKU:- ATP citrate lyase (ACL) catalyzes the synthesis of acetyl-CoA and oxaloacetate using citrate, CoA, and ATP as substrates and Mg2+ as a cofactor.{27878} The ACL-dependent synthesis of acetyl-CoA is important for the de novo synthesis of fatty acids and cholesterol.{27877} Furthermore, as a key enzyme for linking glucose and lipid metabolism, ACL is thought to contribute to the Warburg effect in cancer cells.{27879} BMS 303141 is a cell-permeable, 2-hydroxy-N-arylbenzenesulfonamide that inhibits ACL with an IC50 value of 0.13 µM.{27876} At an oral dose of 100 mg/kg/day, BMS 303141 has been reported to reduce weight gain and lower plasma cholesterol, triglycerides, and glucose in a mouse model of hyperlipidemia.{27876}
Brand:CaymanSKU:-
BMS 345541 is a cell permeable inhibitor of the IκB kinases IKKα and IKKβ (IC50s = 4 and 0.3 µM).{27271} It is without effect against a panel of other serine/threonine and tyrosine kinases at 100 µM.{27271} BMS 345541 inhibits signaling through nuclear factor-κB (NF-κB) both in cells and in vivo, showing excellent pharmacokinetics in mice.{27271} It blocks joint inflammation and damage in collagen-induced arthritis in mice and induces apoptosis in melanoma cells both in vitro and in vivo.{27267,27270} BMS 345541 is used to explore novel roles for IKK phosphorylation and NF-κB signaling.{27268,27269}
Brand:CaymanSKU:-Out of stock
BMS 345541 is a cell permeable inhibitor of the IκB kinases IKKα and IKKβ (IC50s = 4 and 0.3 µM).{27271} It is without effect against a panel of other serine/threonine and tyrosine kinases at 100 µM.{27271} BMS 345541 inhibits signaling through nuclear factor-κB (NF-κB) both in cells and in vivo, showing excellent pharmacokinetics in mice.{27271} It blocks joint inflammation and damage in collagen-induced arthritis in mice and induces apoptosis in melanoma cells both in vitro and in vivo.{27267,27270} BMS 345541 is used to explore novel roles for IKK phosphorylation and NF-κB signaling.{27268,27269}
Brand:CaymanSKU:-Out of stock
BMS 345541 is a cell permeable inhibitor of the IκB kinases IKKα and IKKβ (IC50s = 4 and 0.3 µM).{27271} It is without effect against a panel of other serine/threonine and tyrosine kinases at 100 µM.{27271} BMS 345541 inhibits signaling through nuclear factor-κB (NF-κB) both in cells and in vivo, showing excellent pharmacokinetics in mice.{27271} It blocks joint inflammation and damage in collagen-induced arthritis in mice and induces apoptosis in melanoma cells both in vitro and in vivo.{27267,27270} BMS 345541 is used to explore novel roles for IKK phosphorylation and NF-κB signaling.{27268,27269}
Brand:CaymanSKU:-Out of stock
BMS 345541 is a cell permeable inhibitor of the IκB kinases IKKα and IKKβ (IC50s = 4 and 0.3 µM).{27271} It is without effect against a panel of other serine/threonine and tyrosine kinases at 100 µM.{27271} BMS 345541 inhibits signaling through nuclear factor-κB (NF-κB) both in cells and in vivo, showing excellent pharmacokinetics in mice.{27271} It blocks joint inflammation and damage in collagen-induced arthritis in mice and induces apoptosis in melanoma cells both in vitro and in vivo.{27267,27270} BMS 345541 is used to explore novel roles for IKK phosphorylation and NF-κB signaling.{27268,27269}
Brand:CaymanSKU:-Out of stock